Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (6342)	1/19/1999 10:57:00 AM
From: Biomaven	Respond to of 9719

More details on some H&Q picks discussed earlier: moneycentral.msn.com Peter

To: rkrw who wrote (6342)	1/19/1999 6:56:00 PM
From: Vector1	Read Replies (1) \| Respond to of 9719

<< Raising cash shouldn't be a problem here. >> In a rational environment yes. There have been few biotech financings for under $250m market cap companies in the last 6 months and the ones that have ocurred have not been on great terms for the companies. The lack of cash is a risk. In my opinion CELG has a good likelihood of announcing a new financing this quarter. I will await the terms and decide whether to buy. If it is a solid financing I will be a buyer. Even if I have to pay a higher price I do so knowing a major risk has been removed. In additon even if it is a high quality financing (and there is a good chance it is) the stock may trade down. Investors in many cases react negatively to dilution. V1